August 11, 2014
A California federal judge on Friday refused to toss an antitrust suit by Retrophin Inc. accusing Questcor Pharmaceuticals Inc. of illegally monopolizing certain medical treatment areas through its acquisition and exclusive sales of infantile spasm drug Acthar, saying Retrophin sufficiently pled antitrust claims.